Insmed Incorporated (NASDAQ:INSM) Shares Bought by C WorldWide Group Holding A S

C WorldWide Group Holding A S raised its stake in Insmed Incorporated (NASDAQ:INSM) by 12.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 443,110 shares of the biopharmaceutical company’s stock after acquiring an additional 50,000 shares during the period. C WorldWide Group Holding A S owned 0.50% of Insmed worth $7,816,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Fox Run Management L.L.C. bought a new position in shares of Insmed during the 2nd quarter valued at approximately $387,000. Aperio Group LLC boosted its position in shares of Insmed by 21.0% during the 2nd quarter. Aperio Group LLC now owns 11,402 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 1,977 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Insmed by 54.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 51,800 shares of the biopharmaceutical company’s stock valued at $1,311,000 after acquiring an additional 18,300 shares during the last quarter. Swiss National Bank boosted its position in shares of Insmed by 9.7% during the 2nd quarter. Swiss National Bank now owns 154,100 shares of the biopharmaceutical company’s stock valued at $3,945,000 after acquiring an additional 13,600 shares during the last quarter. Finally, Hillsdale Investment Management Inc. bought a new position in shares of Insmed during the 2nd quarter valued at approximately $740,000.

INSM stock traded up $0.03 during midday trading on Friday, reaching $19.07. The company’s stock had a trading volume of 704,128 shares, compared to its average volume of 1,074,463. The company has a debt-to-equity ratio of 1.19, a quick ratio of 6.70 and a current ratio of 6.97. The stock has a fifty day simple moving average of $18.13 and a two-hundred day simple moving average of $21.80. Insmed Incorporated has a 1 year low of $11.31 and a 1 year high of $33.13. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -4.57 and a beta of 2.97.

Insmed (NASDAQ:INSM) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. The business had revenue of $38.89 million during the quarter, compared to analysts’ expectations of $35.89 million. During the same quarter in the previous year, the business earned ($1.14) EPS. As a group, analysts forecast that Insmed Incorporated will post -2.91 EPS for the current fiscal year.

INSM has been the subject of a number of research reports. Credit Suisse Group reiterated a “buy” rating and set a $40.00 target price on shares of Insmed in a research report on Tuesday, September 10th. Zacks Investment Research lowered Insmed from a “buy” rating to a “hold” rating in a report on Friday, September 27th. ValuEngine lowered Insmed from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. HC Wainwright restated a “buy” rating on shares of Insmed in a report on Thursday, October 31st. Finally, Morgan Stanley set a $37.00 price target on Insmed and gave the company a “buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $35.88.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Recommended Story: What is the definition of market timing?

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply